Donepezil

Generic Name
Donepezil
Brand Names
Adlarity, Aricept, Namzaric
Drug Type
Small Molecule
Chemical Formula
C24H29NO3
CAS Number
120014-06-4
Unique Ingredient Identifier
8SSC91326P
Background

In 2016, the global burden of dementia was estimated to be 43.8 million, demonstrating a significant increase from a global prevalence of 20.2 million in 1990. Donepezil, also known as Aricept, is a piperidine derivative acetylcholinesterase inhibitor used in the management of the dementia of Alzheimer's Disease, and in some cases, is used to manage other ty...

Indication

Donepezil, administered orally or via transdermal delivery system, is indicated for the treatment of dementia of the Alzheimer's type. It is also available as an extended-release capsule in combination with memantine for the treatment of moderate-to-severe dementia of the Alzheimer's type in patients previously stabilized on 10mg of donepezil hydrochloride o...

Associated Conditions
Alzheimer's Disease (AD), Dementia With Lewy Body Disease, Dementia due to Parkinson's disease, Dementia of the Alzheimer's Type, Vascular Dementia (VaD), Moderate Alzheimer's Type Dementia, Severe Alzheimer's Type Dementia
Associated Therapies
-
Clinical Trials
Related News

A Multidisciplinary Approach to Manage Gait Difficulty in Parkinson Patients

First Posted Date
2016-08-05
Last Posted Date
2017-12-12
Lead Sponsor
University of Chicago
Registration Number
NCT02857244
Locations
🇺🇸

University of Chicago Medical Center, Chicago, Illinois, United States

Safety and Efficacy of Donepezil in Mild to Moderate Alzheimer's Disease

Phase 4
Completed
Conditions
Alzheimer's Disease
Interventions
Drug: Donepezil
First Posted Date
2016-06-01
Last Posted Date
2024-08-23
Lead Sponsor
Beijing Friendship Hospital
Target Recruit Count
241
Registration Number
NCT02787746
Locations
🇨🇳

Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing, China

Study of TAK-071 in Healthy Participants and Participants With Mild Cognitive Impairment/Mild Alzheimer Disease and Relative Bioavailability (BA) and Food Effect of TAK-071 in Healthy Participants

First Posted Date
2016-05-11
Last Posted Date
2019-06-10
Lead Sponsor
Takeda
Target Recruit Count
179
Registration Number
NCT02769065

DL-3-n-butylphthalide Treatment in Patients With Mild to Moderate Alzheimer's Disease Already Receiving Donepezil

First Posted Date
2016-03-17
Last Posted Date
2020-02-12
Lead Sponsor
First Affiliated Hospital Xi'an Jiaotong University
Target Recruit Count
92
Registration Number
NCT02711683
Locations
🇨🇳

First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China

A Study of Donepezil Hydrochloride in Patients With Dementia Associated With Cerebrovascular Disease

First Posted Date
2016-01-21
Last Posted Date
2020-01-10
Lead Sponsor
Eisai Co., Ltd.
Target Recruit Count
302
Registration Number
NCT02660983

Investigation of Pharmacokinetic Drug-drug Interaction of BI 409306 and Donepezil in Healthy Male and Female Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: BI 409306
Drug: Donepezil
First Posted Date
2015-12-21
Last Posted Date
2024-08-20
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
32
Registration Number
NCT02635750
Locations
🇩🇪

CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany

SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study

First Posted Date
2015-10-20
Last Posted Date
2023-06-09
Lead Sponsor
Suven Life Sciences Limited
Target Recruit Count
564
Registration Number
NCT02580305
Locations
🇺🇸

Senior Clinical Trials, Inc., Laguna Hills, California, United States

🇺🇸

Emerald Coast Center for Neurological Disorders, Pensacola, Florida, United States

🇺🇸

Neurological Associates of Albany, PC, Albany, New York, United States

and more 67 locations

A Dose Titration Study of CPC-201 in Patients With Dementia of Alzheimer's Type

First Posted Date
2015-09-15
Last Posted Date
2019-03-05
Lead Sponsor
Chase Pharmaceuticals Corporation, an affiliate of Allergan plc
Target Recruit Count
28
Registration Number
NCT02549196
Locations
🇺🇸

PMG Research, Winston-Salem, North Carolina, United States

🇺🇸

Quantum Laboratories, Deerfield Beach, Florida, United States

🇺🇸

Miami Jewish Health Systems, Miami, Florida, United States

and more 1 locations

Optimal Dose Escalation Strategy to Successful Achievement of High Dose Donepezil 23mg

Phase 3
Completed
Conditions
Alzheimer's Disease
Interventions
Drug: donepezil
First Posted Date
2015-09-15
Last Posted Date
2018-08-07
Lead Sponsor
Asan Medical Center
Target Recruit Count
176
Registration Number
NCT02550665
Locations
🇰🇷

Asan Medical Center, Seoul, Korea, Republic of

Effect of Donepezil on Cognition in Parkinson's Disease With Mild Cognitive Impairment (PD-MCI)

Phase 2
Conditions
Parkinson's Disease
Interventions
Drug: Donepezil
First Posted Date
2015-05-21
Last Posted Date
2019-01-29
Lead Sponsor
Yonsei University
Target Recruit Count
80
Registration Number
NCT02450786
Locations
🇰🇷

Severance Hospital, Seoul, Korea, Republic of

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy